Article Text

OP0221 Efficacy and Safety of Tumour Necrosis Factor-Alpha Antagonists in A Large Cohort of Juvenile Dermatomyositis Patients
  1. R. Campanilho-Marques1,2,3,4,
  2. C. Deakin1,
  3. S. Simou1,
  4. L.R. Wedderburn1,5,
  5. C. Pilkington2,
  6. on behalf of Juvenile Dermatomyositis Research Group (JDRG)
  1. 1Infection, Inflammation and Rheumatology Section, UCL, Institute of Child Health
  2. 2Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
  3. 3Rheumatology, Santa Maria Hospital
  4. 4Rheumatology, Instituto Português de Reumatologia, Lisbon, Portugal
  5. 5Arthritis Research UK Centre for Adolescent Rheumatology, UCL, UCLH, GOSH NHS Trust, London, United Kingdom


Background Some patients with juvenile dermatomyositis (JDM) have a disease course which is refractory to multiple drug treatments. There is evidence that prolonged disease activity is associated with increased mortality and morbidity. High levels of anti-TNFα have been reported in JDM patients with a long disease course, suggesting it may play a significant role in refractory disease. There are no published clinical trials of this therapy but some are in progress.

Objectives To evaluate the efficacy and safety of anti-TNFα treatment in UK JDM Cohort and Biomarker Study patients.

Methods Data were analysed from children who were recruited to the UK JDM Cohort and Biomarker Study, met Bohan-Peter criteria and were on anti-TNF treatment at the time of analysis, and had had at least 3 months of therapy. Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8), muscle enzymes and physicians global assessment (PGA) were recorded. Skin disease was assessed using modified skin Disease activity score (DAS).

Results 66 patients with JDM actively treated with anti-TNF agents were analyzed. 41 patients were female (62%). The current mean (±SD) age of these patients was 16.8±5.6 years old, the mean age at diagnosis was 7.31±4.04 years old and the mean disease duration was of 9.6±4.6. Mean disease duration at the beginning of anti-TNF treatment was 3.49±2.80 years and mean duration of anti-TNF therapy was of 2.76±2.09 years. Muscle involvement significantly improved, with median [IQR] CMAS and MMT8 values at initiation of anti-TNF therapy of 45.50 [39.75–52.25] and 74 [59.5–79.5] respectively, and at current evaluation (or date of anti-TNF treatment completion) of 53 [50–53] and 79 [74.5–80] (p<0.0001 and p=0.0097; Mann Whitney test), respectively. For skin involvement the initial modified DAS was 4 [2–5] and final 1 [0–3] (p<0.0001; Mann Whitney test). Assessing global disease activity the initial PGA was 2.9 [1.3–4.3] and final 0.5 [0–1.45] (p<0.0001; Mann Whitney test). Sixteen patients (24%) switched their anti-TNF treatment. 62.5% of the switches were due to therapy failure, 25% due to adverse events and 12.5% for patient preference in subcutaneous administration. Of 21 adverse reactions registered, 7 were considered severe (anaphylactic reactions on infliximab infusion). One patient died due to small bowel perforation (not felt to be related to the use of TNF antagonists). The remaining adverse reactions were not severe and 77% (n=10) of them were due to infections causes. In 4 of the mild to moderate adverse reactions the drug had to be discontinued and switched to another TNF antagonist, while in the remaining patients temporarily withholding the drug proved sufficient. No tuberculosis case was registered.

Conclusions This study is one of the largest to explore the efficacy and safety of TNF antagonist treatment in a large independent cohort of JDM patients. Both muscle and skin involvement appeared to improve after anti-TNF treatment.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.